Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients: a randomized controlled phase 2 trial
Nawal Al Kaabi, Yun Kai Yang, Li Fang Du, Ke Xu, Shuai Shao, Yu Liang, Yun Kang, Ji Guo Su, Jing Zhang, Tian Yang, Salah Hussein, Mohamed Saif ElDein, Sen Sen Yang, Wenwen Lei, Xue Jun Gao, Zhiwei Jiang, Xiangfeng Cong, Yao Tan, Hui Wang, Meng Li, Hanadi Mekki Mekki, Walid Zaher, Sally Mahmoud, Xue Zhang, Chang Qu, Dan Ying Liu, Jing Zhang, Mengjie Yang, Islam Eltantawy, Jun Wei Hou, Ze Hua Lei, Peng Xiao, Zhao Nian Wang, Jin Liang Yin, Xiao Yan Mao, Jin Zhang, Liang Qu, Yun Tao Zhang, Xiao Ming Yang, Guizhen Wu, Qi Ming Li
doi: https://doi.org/10.1101/2022.03.08.22272062
Nawal Al Kaabi
1Sheikh Khalifa Medical City, SEHA, Abu Dhabi, United Arab Emirates
2College of Medicine and Health Sciences, Khalifa University, Abu Dhabi, United Arab Emirates
Yun Kai Yang
3China National Biotec Group Company Limited, Beijing, China
Li Fang Du
4The Sixth Laboratory, National Vaccine and Serum Institute (NVSI), Beijing, China
5National Engineering Center for New Vaccine Research, Beijing, China
Ke Xu
6National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention (China CDC), Beijing, China
Shuai Shao
4The Sixth Laboratory, National Vaccine and Serum Institute (NVSI), Beijing, China
5National Engineering Center for New Vaccine Research, Beijing, China
Yu Liang
4The Sixth Laboratory, National Vaccine and Serum Institute (NVSI), Beijing, China
5National Engineering Center for New Vaccine Research, Beijing, China
Yun Kang
5National Engineering Center for New Vaccine Research, Beijing, China
7Clinical Medicine Office, National Vaccine and Serum Institute (NVSI), Beijing, China
Ji Guo Su
4The Sixth Laboratory, National Vaccine and Serum Institute (NVSI), Beijing, China
5National Engineering Center for New Vaccine Research, Beijing, China
Jing Zhang
4The Sixth Laboratory, National Vaccine and Serum Institute (NVSI), Beijing, China
5National Engineering Center for New Vaccine Research, Beijing, China
Tian Yang
3China National Biotec Group Company Limited, Beijing, China
Salah Hussein
1Sheikh Khalifa Medical City, SEHA, Abu Dhabi, United Arab Emirates
Mohamed Saif ElDein
1Sheikh Khalifa Medical City, SEHA, Abu Dhabi, United Arab Emirates
Sen Sen Yang
5National Engineering Center for New Vaccine Research, Beijing, China
7Clinical Medicine Office, National Vaccine and Serum Institute (NVSI), Beijing, China
Wenwen Lei
6National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention (China CDC), Beijing, China
Xue Jun Gao
8Lanzhou Institute of Biological Products Company Limited, Lanzhou, China
Zhiwei Jiang
9Beijing Key Tech Statistical Consulting Co., Ltd, Beijing, China
Xiangfeng Cong
5National Engineering Center for New Vaccine Research, Beijing, China
7Clinical Medicine Office, National Vaccine and Serum Institute (NVSI), Beijing, China
Yao Tan
5National Engineering Center for New Vaccine Research, Beijing, China
7Clinical Medicine Office, National Vaccine and Serum Institute (NVSI), Beijing, China
Hui Wang
10Beijing Institute of Biological Products Company Limited, Beijing, China
Meng Li
3China National Biotec Group Company Limited, Beijing, China
Hanadi Mekki Mekki
11Union 71, United Arab Emirates
Walid Zaher
12G42 Healthcare, United Arab Emirates
Sally Mahmoud
12G42 Healthcare, United Arab Emirates
Xue Zhang
3China National Biotec Group Company Limited, Beijing, China
Chang Qu
3China National Biotec Group Company Limited, Beijing, China
Dan Ying Liu
3China National Biotec Group Company Limited, Beijing, China
Jing Zhang
6National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention (China CDC), Beijing, China
Mengjie Yang
6National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention (China CDC), Beijing, China
Islam Eltantawy
12G42 Healthcare, United Arab Emirates
Jun Wei Hou
4The Sixth Laboratory, National Vaccine and Serum Institute (NVSI), Beijing, China
5National Engineering Center for New Vaccine Research, Beijing, China
Ze Hua Lei
4The Sixth Laboratory, National Vaccine and Serum Institute (NVSI), Beijing, China
5National Engineering Center for New Vaccine Research, Beijing, China
Peng Xiao
12G42 Healthcare, United Arab Emirates
Zhao Nian Wang
3China National Biotec Group Company Limited, Beijing, China
Jin Liang Yin
3China National Biotec Group Company Limited, Beijing, China
Xiao Yan Mao
8Lanzhou Institute of Biological Products Company Limited, Lanzhou, China
Jin Zhang
10Beijing Institute of Biological Products Company Limited, Beijing, China
Liang Qu
3China National Biotec Group Company Limited, Beijing, China
Yun Tao Zhang
3China National Biotec Group Company Limited, Beijing, China
Xiao Ming Yang
3China National Biotec Group Company Limited, Beijing, China
Guizhen Wu
6National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention (China CDC), Beijing, China
Qi Ming Li
4The Sixth Laboratory, National Vaccine and Serum Institute (NVSI), Beijing, China
5National Engineering Center for New Vaccine Research, Beijing, China
![Loading Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif)
Article usage
Posted March 10, 2022.
Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients: a randomized controlled phase 2 trial
Nawal Al Kaabi, Yun Kai Yang, Li Fang Du, Ke Xu, Shuai Shao, Yu Liang, Yun Kang, Ji Guo Su, Jing Zhang, Tian Yang, Salah Hussein, Mohamed Saif ElDein, Sen Sen Yang, Wenwen Lei, Xue Jun Gao, Zhiwei Jiang, Xiangfeng Cong, Yao Tan, Hui Wang, Meng Li, Hanadi Mekki Mekki, Walid Zaher, Sally Mahmoud, Xue Zhang, Chang Qu, Dan Ying Liu, Jing Zhang, Mengjie Yang, Islam Eltantawy, Jun Wei Hou, Ze Hua Lei, Peng Xiao, Zhao Nian Wang, Jin Liang Yin, Xiao Yan Mao, Jin Zhang, Liang Qu, Yun Tao Zhang, Xiao Ming Yang, Guizhen Wu, Qi Ming Li
medRxiv 2022.03.08.22272062; doi: https://doi.org/10.1101/2022.03.08.22272062
Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients: a randomized controlled phase 2 trial
Nawal Al Kaabi, Yun Kai Yang, Li Fang Du, Ke Xu, Shuai Shao, Yu Liang, Yun Kang, Ji Guo Su, Jing Zhang, Tian Yang, Salah Hussein, Mohamed Saif ElDein, Sen Sen Yang, Wenwen Lei, Xue Jun Gao, Zhiwei Jiang, Xiangfeng Cong, Yao Tan, Hui Wang, Meng Li, Hanadi Mekki Mekki, Walid Zaher, Sally Mahmoud, Xue Zhang, Chang Qu, Dan Ying Liu, Jing Zhang, Mengjie Yang, Islam Eltantawy, Jun Wei Hou, Ze Hua Lei, Peng Xiao, Zhao Nian Wang, Jin Liang Yin, Xiao Yan Mao, Jin Zhang, Liang Qu, Yun Tao Zhang, Xiao Ming Yang, Guizhen Wu, Qi Ming Li
medRxiv 2022.03.08.22272062; doi: https://doi.org/10.1101/2022.03.08.22272062
Subject Area
Subject Areas
- Addiction Medicine (331)
- Allergy and Immunology (655)
- Anesthesia (175)
- Cardiovascular Medicine (2548)
- Dermatology (214)
- Emergency Medicine (387)
- Epidemiology (12030)
- Forensic Medicine (10)
- Gastroenterology (724)
- Genetic and Genomic Medicine (3949)
- Geriatric Medicine (371)
- Health Economics (660)
- Health Informatics (2551)
- Health Policy (983)
- Hematology (354)
- HIV/AIDS (816)
- Medical Education (391)
- Medical Ethics (106)
- Nephrology (420)
- Neurology (3711)
- Nursing (205)
- Nutrition (553)
- Oncology (1929)
- Ophthalmology (560)
- Orthopedics (231)
- Otolaryngology (299)
- Pain Medicine (245)
- Palliative Medicine (71)
- Pathology (467)
- Pediatrics (1081)
- Primary Care Research (440)
- Public and Global Health (6379)
- Radiology and Imaging (1346)
- Respiratory Medicine (851)
- Rheumatology (389)
- Sports Medicine (336)
- Surgery (427)
- Toxicology (51)
- Transplantation (184)
- Urology (159)